Skip to main content
Caplight Logo









Cyclomics B.V.

Cyclomics B.V.

Private
AmsterdamHealthcare & Life Scienceshttps://www.cyclomics.com/

Last Round

VC Round

Jan 8, 2026

Total Funding Raised

$29,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cyclomics B.V. is a biotechnology company that develops liquid biopsy-based diagnostic solutions for cancer detection and monitoring.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Application

Keywords

circulating tumor DNActDNAliquid biopsylong-read sequencingcancer diagnosticsprecision medicinein vitro diagnosticIVDbioinformaticsclinical AIgenomic datamolecular diagnosticsAI pathologycancer screeningbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cyclomics B.V. Comparables

Compare Cyclomics B.V. with similar companies based on industry and business-model similarity.

Cyclomics B.V. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biofidelity
84%
Nonacus
81%
Lucence
77%

Cyclomics B.V. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 8, 2026
SeedMar 2, 2023
AcceleratorNov 22, 2017

Key People

Founding team and executive leadership

Jeroen de Ridder

co-founder and CTO

Founding Team

Cyclomics B.V. Investors

Notable investors and investment history

Cyclomics B.V. investors
InvestorRounds
Life Sciences @ Work Venture ChallengeAccelerator
Myosotis InvestmentsVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 15, 2026

    Grew 27% QoQ from 11 to 14 employees.

  • Jul 18, 2026

    Grew 30% QoQ, from 10 to 13 employees.

Cyclomics B.V. Filings

Explore SEC and related filing metadata, where available.

Cyclomics B.V. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cyclomics B.V.'s valuation, stock price, and market status.

Is Cyclomics B.V. a public or private company?

Cyclomics B.V. is a private company.

What is the current stock price of Cyclomics B.V.?

Cyclomics B.V. is a private company with no public stock price. No recent secondary market data is available.

How much is Cyclomics B.V. worth (valuation)?

Valuation information for Cyclomics B.V. is not publicly available.

Can I buy Cyclomics B.V. stock?

Cyclomics B.V. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cyclomics B.V.'s last funding round?

Cyclomics B.V.'s most recent funding round was VC Round on January 8, 2026.

Who are the main investors in Cyclomics B.V.?

Key investors in Cyclomics B.V. include Myosotis Investments.

Will Cyclomics B.V. IPO soon?

No public IPO plans have been announced for Cyclomics B.V..

How can I track Cyclomics B.V. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cyclomics B.V.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAmsterdam
Employee Range13
Year Founded2018
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?